Concentration of adiponectin in relation to insulin resistance in patients with type 2 diabetes
DOI:
https://doi.org/10.12923/Keywords:
diabetes, obesity, insulin resistance, adiponectinAbstract
During the past few years a lot of attention has been paid to the potential role of adipose tissue in the development of type 2 diabetes Recent research studies have shown that adipose tissue is not only a passive depot storing triglyceride but also an active endocrine organ, which plays a key role in the integration of endocrine, metabolic, and inflammatory signals for the control of energy homeostasis secreting a variety of hormones and cytokines known as adipocytokines. One of these proteins that have attracted a lot of attention recently is adiponectin. Many experimental and clinical studies have suggested that low levels of adiponectin contribute to insulin resistance associated with obesity thus increasing the risk of developing type 2 diabetes. The aim of this study was to compare serum adiponectin concentration between overweight and obese patients with type 2 diabetes and normal-weight subjects with no disturbances in carbohydrate metabolism and to evaluate the relationship between serum adiponectin concentration and metabolic parameters, such as insulin resistance indexes (IRI/G, HOMA-IR) and Quantitative Insulin Sensitivity Check Index in diabetic patients. Forty-five patients with type 2 diabetes were enrolled in this study (22 women and 23 men with mean age 60.1±10.3 years). The control group comprised 25 healthy subjects matched for age and gender to the study group. In diabetic patients the concentration of adiponectin was significantly lower compared to the control subjects. We observed significant negative correlations between adiponectin concentration and body mass, BMI, glucose and insulin level and values of HOMA-IR and IRI/G indexes. Furthermore, significant positive correlations were found between adiponectin concentration and age and values of QUICKI index. Taking into account the available literature reports as well as the results obtained during this study, it can be concluded that decreased adiponectin concentration in overweight and obese patients with type 2 diabetes in comparison to healthy subjects and the observed correlations of adiponectin with selected indexes of insulin resistance (IRI/G, HOMA-IR, QUICKI) may suggest a participation of this protein in the pathogenesis of insulin resistance in diabetic patients.
References
1. Abbasi F., Chu J.W., Lamendola C. et al: Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes, 53, 585, 2004.
2. Arita Y., Kihara S., Ouchi N. et al: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun., 257, 79, 1999.
3. Cnop M., Havel P.J., Utzschneider K.M. et al: Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia,46, 459, 2003.
4. Daimon M., Oizumi T., Saitoh T. et al:. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese population. Diabetes Care, 26, 2015, 2003.
5. Esteghamati A., Alamdari A., Zandieh A. et al: Serum visfatin is associated with type 2 diabetes mellitus independent of insulin resistance and obesity. Diabetes Res. Clin. Pract., 91(2), 154, 2011.
6. Gastaldelli A.: Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 93(1), 60, 2011.
7. Havel P.J.: Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism. Diabetes, 53(1), 143, 2004.
8. Hotta K., Funahashi T., Arita Y. et al: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol., 20, 1595, 2000.
9. Hotta K., Funahashi T., Bodkin N.L. et al: Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes, 50, 1126, 2001.
10. Hu E., Liang P., Spiegelman B.M.: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem., 271, 10697, 1996.
11. Ioannis K., Sudhesh K.: Weight Management in Overweight and Obese Patients With Type 2 Diabetes Mellitus. The Br. J. Diabetes Vasc. Dis., 10(6), 274, 2010.
12. Jin H., Jiang B., Tang J. et al: Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res. Clin. Pract., 79(3), 412, 2008.
13. Kadowaki T., Yamauchi T., Kubota N. et al: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest., 116, 1784, 2006.
14. Katz A., Nambi S.S., Mather K. et al: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J. Clin. Endocrinol. Metab., 85, 2402, 2000.
15. Kern P.A., Di Gregorio G.B., Lu T. et al: Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes, 52, 1779, 2003.
16. Kim D.M., Yoon S.J., Ahn C.W. et al: Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. Diabetes Res. Clin. Pract., 66 (1), 139, 2004.
17. Kowalska I.: Role of adipose tissue in the development of vascular complications in type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 78 (1), 14, 2007.
18. Kondo H, Shimomura I., Matsukawa Y. et a.: Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes, 51(7), 2325, 2002.
19. Lan J., Chen X., Wang S. et al: The relationship between visfatin and HOMA-IR in hypertensive patients, and the effect of antihypertensive drugs on visfatin and HOMA-IR in hypertensive patients with insulin resistance. Diabetes Res. Clin. Pract., 8, 2011.
20. Lindsay R.S., Funahashi T., Hanson R.L. et al: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet, 360, 57, 2002.
21. Maeda N., Shimomura I., Kishida K. et al: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med., 8, 731, 2002.
22. Mathews D.R., Hosker J.P., Rudenski A.S. et al: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412, 1985.
23. Nakatochi M., Miyata S., Tanimura D. et al: The ratio of adiponectin to homeostasis model assessment of insulin resistance is a powerful index of each component of metabolic syndrome in an aged Japanese population. Diabetes Res. Clin. Pract., 92(3), 61, 2011.
24. Okamoto Y., Kihara S., Funahashi T. et al: Adiponectin: a key adipocytokine in metabolic syndrome. Clin. Sci. (Lond)., 110(3), 267, 2006.
25. Phillips L.K., Prins J.B.: The link between abdominal obesity and the metabolic syndrome. Current Hypertension Reports, 10(2), 156, 2008.
26. Ryo, M., Nakamura, T., Kihara, S. et al: Adiponectin as a biomarker of the metabolic syndrome. Circ. J., 68, 975, 2004.
27. Shah S., Gavrila A., Mantzoros C.S. (2005). Adiponectin and the Cardiovascular System. In: Diabetes and Cardiovascular Disease. Johnstone Michael T., Veves Aristidis (editors). Boston: Humana Press; p.191.
28. Siminerio L., Mbanya J.C.: Translating diabetes research into global communities. Diabetes Res. Clin. Pract., 93(3), 443, 2011.
29. Spranger J., Kroke A., Mohlig M. et al: Adiponectin and protection against type 2 diabetes mellitus. Lancet, 361, 226, 2003.
30. Stefan N., Stumvoll M., Vozarova B. et al: Plasma adiponectin and endogenous glucose production in humans. Diabetes Care, 26, 3315, 2003.
31. Stefanović A., Kotur-Stevuljević J., Spasić S. et al: The influence of obesity on the oxidative stress status and the concentration of leptin in type 2 diabetes mellitus patients. Diabetes Res. Clin. Pract., 79(1), 156, 2008.
32. Tilg H., Wolf A.M.: Adiponectin: a key fat-derived molecule regulating inflammation. Expert. Opin. Ther. Targets, 9(2), 245, 2005.
33. Trujillo M.E., Scherer P.E.: Adiponectin-journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med., 257(2), 167, 2005.
34. Tschritter O., Fritsche A., Thamer C. et al: Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes, 52, 239, 2003.
35. Vendramini M.F., Ferreira S.R., Gimeno S.G. et al: Plasma adiponectin levels and incident glucose intolerance in Japanese-Brazilians: a seven-year follow-up study. Diabetes Res. Clin. Pract. 73(3), 304, 2006.
36. Weyer C., Funahashi T., Tanaka S. et al: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J. Clin. Endocrinol. Metab., 86, 193, 2001.
37. Yamamoto Y., Hirose H., Saito I. et al: Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin. Sci. (Lond), 103, 137, 2002.
38. Zhuo Q., Wang Z., Fu P. et al: Comparison of adiponectin, leptin and leptin to adiponectin ratio as diagnostic marker for metabolic syndrome in older adults of Chinese major cities. Diabetes Res. Clin. Pract., 84(1), 27, 2009.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
